Q-omics provides the consensus-scored HDAC1 profile across patient tissues and cancer cell-line models. HDAC1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, HDAC1 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, HDAC1 protein abundance shows 29,362 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, HNSC, and GBM as cancer lineages where HDAC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HDAC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HDAC1 survival associations across molecular data types. HDAC1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HDAC1 RNA expression–survival associations across cancer types. High HDAC1 expression shows unfavorable associations in KICH, LIHC, OV, LGG and ACC, but favorable associations in SCLC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for HDAC1 RNA expression.
This table summarizes HDAC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for HDAC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HDAC1 shows lower tumor expression in KICH and higher tumor expression in HNSC, LUSC, LUAD, STAD and LIHC. The HNSC box plot shows higher HDAC1 RNA expression in tumor versus normal tissue (log2 FC = +0.868, t-test p < 0.001).
This table shows molecular features associated with HDAC1 in patient tissues and cancer cell lines. In patient samples, HDAC1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HDAC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
